<DOC>
	<DOC>NCT00809328</DOC>
	<brief_summary>Azithromycin has high rates of clinical response and eradication, wide spectrum of activity, so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community acquired pneumonia.</brief_summary>
	<brief_title>The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<criteria>16 years of age or older patients with CAP. Patients who were diagnosed as moderate in severity. Known or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or ketolides. Hepatic dysfunction (AST, ALT, total bilirubin &gt; 3 times institutional normal). Severe renal dysfunction (creatinine clearance &lt; 30 ml/min). Patients who have a history of severe heart diseases (4th degree of NYHA). Patients who have a congenital or sporadic long QT syndrome, or who are received the drugs with reported QT prolongation. Severe underlying disease.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>